L&T Eyes $50-$60 Billion Projects by FY25, Plans Major O2C Investments
Subsidiary of Aurobindo Pharma receives USFDA’s final approval for Carboprost Tromethamine Injection!
Last Updated: 26th May 2023 - 04:40 pm
Shares of the company have gained more than 35% on a YTD basis.
Product has an estimated market size of around $51.4 million
Aurobindo Pharma’s wholly owned subsidiary company - Eugia Pharma Specialties has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, Single-Dose Vials, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Hemabate Injection, 250mcg/mL, of Pfizer Inc. The product is expected to be launched in June 2023.
The approved product has an estimated market size of around $51.4 million for the twelve months ending March 2023, according to IQVIA. This is the 159th approved ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile speciality products.
Share price movement of Aurobindo Pharm Limited
Today, the stock opened at Rs 599.55, with a high and low of Rs 606.85 and Rs 596.45. Currently, the stock is trading at Rs 604.45, down by 0.12%.
In the last six months, the shares of the company have given about 28 per cent returns and in the last 1 year, the stock has given about 10% returns.
The stock has a 52-week high of Rs 647.90 and a 52-week low of Rs 397.30. The company has a ROCE of 12.9% and an ROE of 11.7% with a market capitalisation of Rs 35,420 crore.
Company profile
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments. Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US.
Trending on 5paisa
05
Tanushree Jaiswal
Discover more of what matters to you.
Indian Market Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.